India’s 1st COVID-19 drug FabiFlu launched, priced at ₹103/tablet
Drug firm Glenmark Pharmaceuticals on Saturday said that it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate coronavirus symptoms at a price of around
Drug firm Glenmark Pharmaceuticals on Saturday said that it has launched antiviral drug Favipiravir, under the brand name FabiFlu, for the treatment of patients with mild to moderate coronavirus symptoms at a price of around ₹103 per tablet. FabiFlu is India’s first oral antiviral drug for the treatment of mild and moderate COVID-19 patients, Glenmark Pharmaceuticals added.
